{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:13:01Z","timestamp":1794366781808,"version":"4.9.0"},"reference-count":36,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T00:00:00Z","timestamp":1563840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_termsofuse.html"}],"funder":[{"DOI":"10.13039\/na","name":"National Cancer Institute, Center for Cancer Research","doi-asserted-by":"publisher","award":["ZIA BC011513"],"award-info":[{"award-number":["ZIA BC011513"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,20]]},"abstract":"<jats:title>Conspectus<\/jats:title>\n                  <jats:p>This Account is the first comprehensive review article on the newly developed, photochemistry-based cancer therapy near-infrared (NIR) photoimmunotherapy (PIT). NIR-PIT is a molecularly targeted phototherapy for cancer that is based on injecting a conjugate of a near-infrared, water-soluble, silicon-phthalocyanine derivative, IRdye700DX (IR700), and a monoclonal antibody (mAb) that targets an expressed antigen on the cancer cell surface. Subsequent local exposure to NIR light turns on this photochemical \u201cdeath\u201d switch, resulting in the rapid and highly selective immunogenic cell death (ICD) of targeted cancer cells. ICD occurs as early as 1 min after exposure to NIR light and results in irreversible morphologic changes only in target-expressing cells based on the newly discovered photoinduced ligand release reaction that induces physical changes on conjugated antibody\/antigen complex resulting in functional damage on cell membrane. Meanwhile, immediately adjacent receptor-negative cells are totally unharmed. Because of its highly targeted nature, NIR-PIT carries few side effects and healing is rapid. Evaluation of the tumor microenvironment reveals that ICD induced by NIR-PIT results in rapid maturation of immature dendritic cells adjacent to dying cancer cells initiating a host anticancer immune response, resulting in repriming of polyclonal CD8+T cells against various released cancer antigens, which amplifies the therapeutic effect of NIR-PIT. NIR-PIT can target and treat virtually any cell surface antigens including cancer stem cell markers, that is, CD44 and CD133. A first-in-human phase 1\/2 clinical trial of NIR-PIT using cetuximab-IR700 (RM1929) targeting EGFR in inoperable recurrent head and neck cancer patients successfully concluded in 2017 and led to \u201cfast tracking\u201d by the FDA and a phase 3 trial (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03769506) that is currently underway in 3 countries in Asia, US\/Canada, and 4 countries in EU. The next step for NIR-PIT is to further exploit the immune response. Preclinical research in animals with intact immune systems has shown that NIT-PIT targeting of immunosuppressor cells within the tumor, such as regulatory T-cells, can further enhance tumor-cell-selective systemic host-immunity leading to significant responses in distant metastatic tumors, which are not treated with light. By combining cancer-targeting NIR-PIT and immune-activating NIR-PIT or other cancer immunotherapies, NIR-PIT of a local tumor, could lead to responses in distant metastases and may also inhibit recurrences due to activation of systemic anticancer immunity and long-term immune memory without the systemic autoimmune adverse effects often associated with immune checkpoint inhibitors. Furthermore, NIR-PIT also enhances nanodrug delivery into tumors up to 24-fold superior to untreated tumors with conventional EPR effects by intensively damaging cancer cells behind tumor vessels. We conclude by describing future advances in this novel photochemical cancer therapy that are likely to further enhance the efficacy of NIR-PIT.<\/jats:p>","DOI":"10.1021\/acs.accounts.9b00273","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T15:37:32Z","timestamp":1563896252000},"page":"2332-2339","source":"Crossref","is-referenced-by-count":475,"title":["Near-Infrared Photoimmunotherapy of Cancer"],"prefix":"10.1021","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1019-4112","authenticated-orcid":true,"given":"Hisataka","family":"Kobayashi","sequence":"first","affiliation":[{"name":"National Cancer Institute, National Institutes of Health , , Building 10, Room B3B69, MSC1088 , , ,","place":["Bethesda, Maryland, United States, 20892-1088"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Choyke","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health , , Building 10, Room B3B69, MSC1088 , , ,","place":["Bethesda, Maryland, United States, 20892-1088"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2019,7,23]]},"reference":[{"key":"2026090213063156600_cit1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3389\/fimmu.2017.00829","article-title":"Cancer Immunotherapy:\nHistorical Perspective of a Clinical Revolution and Emerging Preclinical\nAnimal Models","volume":"8","author":"Decker","year":"2017","journal-title":"Front. Immunol."},{"key":"2026090213063156600_cit2","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/j.molonc.2015.10.009","article-title":"Cancer immunotherapy:\nStrategies for personalization\nand combinatorial approaches","volume":"9","author":"Sathyanarayanan","year":"2015","journal-title":"Mol. Oncol."},{"key":"2026090213063156600_cit3","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/nm.2554","article-title":"Cancer cell-selective\nin vivo near\ninfrared photoimmunotherapy targeting specific membrane molecules","volume":"17","author":"Mitsunaga","year":"2011","journal-title":"Nat. Med."},{"key":"2026090213063156600_cit4","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1021\/acscentsci.8b00565","article-title":"Photoinduced\nLigand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal\nAntibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared\nPhotoimmunotherapy","volume":"4","author":"Sato","year":"2018","journal-title":"ACS Cent. Sci."},{"key":"2026090213063156600_cit5","doi-asserted-by":"publisher","first-page":"10425","DOI":"10.18632\/oncotarget.14425","article-title":"Immunogenic\ncancer cell death selectively induced by near infrared photoimmunotherapy\ninitiates host tumor immunity","volume":"8","author":"Ogawa","year":"2017","journal-title":"Oncotarget"},{"key":"2026090213063156600_cit6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2326-6066.CIR-18-0546","article-title":"Host Immunity\nFollowing Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint\nBlockade to Eradicate Established Antigenic Tumors","volume":"7","author":"Nagaya","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"2026090213063156600_cit7","doi-asserted-by":"publisher","first-page":"352ra110","DOI":"10.1126\/scitranslmed.aaf6843","article-title":"Spatially\nselective depletion of tumor-associated regulatory T cells with near-infrared\nphotoimmunotherapy","volume":"8","author":"Sato","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"2026090213063156600_cit8","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1158\/1541-7786.MCR-17-0164","article-title":"Near-Infrared\nPhotoimmunotherapy\nTargeting Prostate Cancer with Prostate-Specific Membrane Antigen\n(PSMA) Antibody","volume":"15","author":"Nagaya","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"2026090213063156600_cit9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121989","article-title":"Near infra-red\nphotoimmunotherapy\nwith anti-CEA-IR700 results in extensive tumor lysis and a significant\ndecrease in tumor burden in orthotopic mouse models of pancreatic\ncancer","volume":"10","author":"Maawy","year":"2015","journal-title":"PLoS One"},{"key":"2026090213063156600_cit10","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1021\/acs.molpharmaceut.5b00132","article-title":"Glypican-3\ntargeted human heavy chain antibody as a drug carrier for hepatocellular\ncarcinoma therapy","volume":"12","author":"Hanaoka","year":"2015","journal-title":"Mol. Pharmaceutics"},{"key":"2026090213063156600_cit11","doi-asserted-by":"publisher","first-page":"23361","DOI":"10.18632\/oncotarget.8025","article-title":"Near infrared\nphotoimmunotherapy with an anti-mesothelin antibody","volume":"7","author":"Nagaya","year":"2016","journal-title":"Oncotarget"},{"key":"2026090213063156600_cit12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.7150\/thno.5908","article-title":"Improving\nthe efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody\nconjugates in a multiple antigen tumor model","volume":"3","author":"Nakajima","year":"2013","journal-title":"Theranostics"},{"key":"2026090213063156600_cit13","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.molonc.2016.07.010","article-title":"Near infrared\nphotoimmunotherapy of B-cell lymphoma","volume":"10","author":"Nagaya","year":"2016","journal-title":"Mol.\nOncol."},{"key":"2026090213063156600_cit14","doi-asserted-by":"publisher","first-page":"8807","DOI":"10.18632\/oncotarget.12410","article-title":"Near infrared\nphotoimmunotherapy with avelumab, an anti-programmed death-ligand\n1 (PD-L1) antibody","volume":"8","author":"Nagaya","year":"2017","journal-title":"Oncotarget"},{"key":"2026090213063156600_cit15","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1158\/1541-7786.MCR-17-0333","article-title":"Syngeneic\nMouse Models of Oral Cancer Are Effectively Targeted by Anti-CD44-Based\nNIR-PIT","volume":"15","author":"Nagaya","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"2026090213063156600_cit16","doi-asserted-by":"publisher","first-page":"27871","DOI":"10.1038\/srep27871","article-title":"Phototheranostics\nof CD44-positive cell populations\nin triple negative breast cancer","volume":"6","author":"Jin","year":"2016","journal-title":"Sci. Rep."},{"key":"2026090213063156600_cit17","doi-asserted-by":"publisher","first-page":"862","DOI":"10.7150\/thno.12890","article-title":"Imaging and\nSelective Elimination of Glioblastoma Stem Cells with Theranostic\nNear-Infrared-Labeled CD133-Specific Antibodies","volume":"6","author":"Jing","year":"2016","journal-title":"Theranostics"},{"key":"2026090213063156600_cit18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113276","article-title":"Photoimmunotherapy\nof gastric cancer\nperitoneal carcinomatosis in a mouse model","volume":"9","author":"Sato","year":"2014","journal-title":"PLoS One"},{"key":"2026090213063156600_cit19","doi-asserted-by":"publisher","first-page":"698","DOI":"10.7150\/thno.11559","article-title":"Near infrared\nphotoimmunotherapy in the treatment of pleural disseminated NSCLC:\npreclinical experience","volume":"5","author":"Sato","year":"2015","journal-title":"Theranostics"},{"key":"2026090213063156600_cit20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.canlet.2015.05.018","article-title":"Near infrared\nphotoimmunotherapy for lung metastases","volume":"365","author":"Sato","year":"2015","journal-title":"Cancer\nLett."},{"key":"2026090213063156600_cit21","doi-asserted-by":"publisher","first-page":"19747","DOI":"10.18632\/oncotarget.3850","article-title":"Near infrared photoimmunotherapy prevents lung cancer\nmetastases in a murine model","volume":"6","author":"Sato","year":"2015","journal-title":"Oncotarget"},{"key":"2026090213063156600_cit22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/1471-2407-12-345","article-title":"Immediate\nin vivo target-specific\ncancer cell death after near infrared photoimmunotherapy","volume":"12","author":"Mitsunaga","year":"2012","journal-title":"BMC Cancer"},{"key":"2026090213063156600_cit23","doi-asserted-by":"publisher","first-page":"R61","DOI":"10.1186\/bcr3167","article-title":"In vivo breast\ncancer characterization imaging using two monoclonal antibodies activatably\nlabeled with near infrared fluorophores","volume":"14","author":"Sano","year":"2012","journal-title":"Breast\nCancer Res."},{"key":"2026090213063156600_cit24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/1535-7163.MCT-16-0663","article-title":"Near Infrared\nPhotoimmunotherapy\nin a Transgenic Mouse Model of Spontaneous Epidermal Growth Factor\nReceptor (EGFR)-expressing Lung Cancer","volume":"16","author":"Nakamura","year":"2017","journal-title":"Mol.\nCancer Ther."},{"key":"2026090213063156600_cit25","doi-asserted-by":"publisher","first-page":"11159","DOI":"10.18632\/oncotarget.24329","article-title":"Interstitial near-infrared photoimmunotherapy:\neffective treatment areas and light doses needed for use with fiber\noptic diffusers","volume":"9","author":"Okuyama","year":"2018","journal-title":"Oncotarget"},{"key":"2026090213063156600_cit26","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1111\/cas.13621","article-title":"Endoscopic\nnear infrared photoimmunotherapy using a\nfiber optic diffuser for peritoneal dissemination of gastric cancer","volume":"109","author":"Nagaya","year":"2018","journal-title":"Cancer Sci."},{"key":"2026090213063156600_cit27","doi-asserted-by":"publisher","first-page":"770","DOI":"10.2967\/jnumed.112.112110","article-title":"Acute Cytotoxic\nEffects of Photoimmunotherapy Assessed by 18F-FDG PET","volume":"54","author":"Sano","year":"2013","journal-title":"J. Nucl. Med."},{"key":"2026090213063156600_cit28","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1158\/0008-5472.CAN-12-1298","article-title":"Real-time\nmonitoring of in vivo acute necrotic cancer cell death induced by\nnear infrared photoimmunotherapy using fluorescence lifetime imaging","volume":"72","author":"Nakajima","year":"2012","journal-title":"Cancer Res."},{"key":"2026090213063156600_cit29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1021\/nn305011p","article-title":"Markedly enhanced\npermeability and retention effects induced by photo-immunotherapy\nof tumors","volume":"7","author":"Sano","year":"2013","journal-title":"ACS Nano"},{"key":"2026090213063156600_cit30","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.2217\/nnm.14.194","article-title":"Photoimmunotherapy\nof hepatocellular carcinoma-targeting\nGlypican-3 combined with nanosized albumin-bound paclitaxel","volume":"10","author":"Hanaoka","year":"2015","journal-title":"Nanomedicine (London, U. K.)"},{"key":"2026090213063156600_cit31","doi-asserted-by":"publisher","first-page":"098004","DOI":"10.1117\/1.JBO.19.9.098004","article-title":"Real-time\nmonitoring of hemodynamic\nchanges in tumor vessels during photoimmunotherapy using optical coherence\ntomography","volume":"19","author":"Liang","year":"2014","journal-title":"J. Biomed. Opt."},{"key":"2026090213063156600_cit32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jconrel.2017.06.004","article-title":"Real-time monitoring\nof microdistribution\nof antibody-photon absorber conjugates during photoimmunotherapy in\nvivo","volume":"260","author":"Tang","year":"2017","journal-title":"J. Controlled Release"},{"key":"2026090213063156600_cit33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2018.04.027","article-title":"3D mesoscopic fluorescence\ntomography for imaging micro-distribution of antibody-photon absorber\nconjugates during near infrared photoimmunotherapy in vivo","volume":"279","author":"Tang","year":"2018","journal-title":"J. Controlled Release"},{"key":"2026090213063156600_cit34","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1158\/1535-7163.MCT-17-0851","article-title":"Molecularly Targeted Cancer Combination Therapy with\nNear-Infrared Photoimmunotherapy and Near-Infrared Photorelease with\nDuocarmycin-Antibody Conjugate","volume":"17","author":"Nagaya","year":"2018","journal-title":"Mol. Cancer\nTher."},{"key":"2026090213063156600_cit35","doi-asserted-by":"publisher","first-page":"25105","DOI":"10.1039\/C4RA13835J","article-title":"Selective\ncell elimination in vitro and in vivo from tissues and tumors using\nantibodies conjugated with a near infrared phthalocyanine","volume":"5","author":"Sato","year":"2015","journal-title":"RSC Adv."},{"issue":"109","key":"2026090213063156600_cit36","doi-asserted-by":"publisher","DOI":"10.3791\/53633","article-title":"Selective Cell Elimination from Mixed\n3D Culture Using a Near Infrared Photoimmunotherapy Technique","author":"Sato","year":"2016","journal-title":"J. Visualized Exp."}],"container-title":["Accounts of Chemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.accounts.9b00273","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/achre4\/article-pdf\/52\/8\/2332\/66936976\/acs.accounts.9b00273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/achre4\/article-pdf\/52\/8\/2332\/66936976\/acs.accounts.9b00273.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:06:36Z","timestamp":1788368796000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/achre4\/article\/52\/8\/2332\/1264464\/Near-Infrared-Photoimmunotherapy-of-Cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,23]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,7,23]]},"published-print":{"date-parts":[[2019,8,20]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.accounts.9b00273","relation":{},"ISSN":["0001-4842","1520-4898"],"issn-type":[{"value":"0001-4842","type":"print"},{"value":"1520-4898","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,23]]}}}